基石药业-B2023年年报

(Incorporated in the Cayman Islands with limited liability)( 於開曼群島註冊成立的有限公司 )Stock Code股份代號 :2616 2103 4104 6106 16107 17109 34180 78 99 ʮ̡༟ࣘ Kenneth Walton Hitchner III Kenneth Walton Hitchner III Paul Herbert Chew www.cstonepharma.com Paul Herbert Chew Vistra (Cayman) LimitedP.O. Box 31119, Grand PavilionHibiscus Way802 West Bay RoadGrand Cayman KY1-1205Cayman Islands Paul Herbert Chew 218C1 Paul Herbert Chew 24840 Paul Herbert Chew Walkers Corporate LimitedCayman Corporate Centre27 Hospital RoadGeorge TownGrand Cayman KY1-9008Cayman Islands 2616 •8835 183171712-1716 826 717710 ࠅৌਕ࿜ •463.8336.795.731.410.18.6%17.53.6% •614.286.4527.8 •249.166.4182.7 •327.3128.0199.3 •902.7535.559.3%367.2 •559.124.4534.7 •489.3151.1338.2•760.6430.456.6%330.2 ࠅุਕ࿜ 463.8368.1336.731.4199.5Les Laboratoires Servier179.5 NDARETNSCLCNSCLCRETNSCLCRETMTCRETTCR/R/TENKTLESCCGC/GEJ NDAIVNSCLCIVNSCLCEMACROIVNSCLCGCP CS5001CS50011ROR1ADCFIHCS5001CS5001ROR1 ADC c-rosoncogene 1ROS1NSCLCnofazinlimabLENVIMA®(lenvatinib)HCCIII ASCOESMOESMOESMOGINatureMedicineNature Cancer CPTADCPCC nofazinlimab製藥三生製藥nofazinlimabCMC®544® CDECDE I. • RET®®®® ®5® • ®RETNSCLC ®RETNSCLCRETMTCRETTC ࠅุਕ࿜ ®ESCC®R/R ENKTL®GC/GEJC • ®2023PDGFRA18PDGFRA D842VGIST ®®PAP • ®®®21NSCLCTCGISTSMAMLCSCOCSCOCACA I I TRWSRWS®GISTIIT®KIT D816N822R/RCBF-AML • ® ®IIINSCLCCSCOCSCO®IIINSCLC II. •CS5001(LCB71 ROR1 ADC) BICROR1 ADCFIH FIH7CS5001CS5001ROR1 ADC 9DLTMTDROR1CS500145CS5001PKADC5BDLBCLCS50012RP2DIb/II(ASCOESMOASH C S5001EMMAEROR1ADCCS5001陰BICCS5001ROR1/13ADCADCCS5001 ROR1ROR1IHC ࠅุਕ࿜ •CS1001PD-L1 IVNSCLC •IVNSCLCMAANSCLCMAAEMAMHRAEMAGCPMHRA80RFIEMA180LoOIEMACROGCP •IVNSCLCGEMSTONE-302OSNature Cancer GC/GEJC •GC/GEJC(CPS≥5)NDA•G C / G E J C(CPS≥5)NDA•GEMSTONE-303PFSOSLBAESMOPFSOS –ESCC •ESCCNDA•ESCCNDA•E S C CGEMSTONE-304PFSOSESMO GI•GEMSTONE-304PFSOSNature Medicine R/R ENKTL •R/R ENKTLNDA•R/R ENKTLGEMSTONE-201•R/RENKTLB •NofazinlimabCS1003 PD-1 •nofazinlimabLENVIMA®(lenvatinib)HCCIIIiDMCOS•nofazinlimabFIH(CS1003-101)(British Journal of Cancer) ࠅุਕ࿜ •CS3009RET RETNSCLCRETMTCRETTCNDATFDARETNSCLCNDAR E TN S C L CI / I IA R R O WCancer •CS3007KIT/PDGFRA B l u e p r i n tM e d i c i n e s C o r p o r a t i o nB l u e p r i n tMedicinesFDAISM BlueprintMedicinesEMAGISTG I S T1N A V I G A T O R1 / 2(CS3007-101)Clinical Cancer Research •CS3010IDH1 R/RAMLR/R AMLR/R AML •ALK/ROS-1 ROS1NSCLCROS1NSCLCpre-NDA/NDA III. ADC •FIC/BICADCADCADCCS5006GPCR-xADC CS5005ADCINDCS5007ADCCS2011CS5007(CS2011)ADC •CS2009PD-1VEGFaCTLA-4INDP D - ( L )1NSCLCHCC • IV. 製藥nofazinlimab製藥nofazinlimabnofazinlimabCMC ࠅุਕ࿜ 544 CTLA-4(CS1002)CS1002HCCNSCLCIb/IICS1002(SHR-8068)adebrelimabNSCLCIND EQRxnofazinlimabnofazinlimabEMAMHRAMAAEQRxnofazinlimab V. CDE •CHMPIVNSCLCMAAMAAIVNSCLCMAA •ROS1NSCLCpre-NDA/NDA •ANDA •NofazinlimabOS•CS5001ASCOESMO/ASHBD•CS2009HRECCTNIND•CS5006IND•CS5005IND ᗘߧࢩ˴ RET®nofazinlimabPD-1®®®® 2.0CS5001(ROR1 ADC)CS5001CS5001ROR1ADCCS5001 ADCPD-1,CTLA-4,VEGFaCS2009INDADCPCC PD-L1NMPAPD-L1IV(EMA)(GCP)2024 ၍ଣᄴীሞʿʱؓ 1214NDA ၍ଣᄴীሞʿʱؓ •® ®RETRETNSCLCRETNSCLCRETMTCRETTCRETNSCLCTFDARETNSCLCRETMTCRETTC RET®®®® ®11NSCLCTC®CSCONSCLCRET®RETNSCLC ®®PAP •® ®KIT/PDGFRAPDGFRA18PDGFRA D842VGIST®TFDAPDGFRA D842VGIST ®®PDGFRA18PDGFRAD842VGIST ®®CSCO IITRWSRWS®GISTIIT®KIT D816N822R/R CBF-AML •® ®IDH1IDH1R/RAML ®5® ®IDH1AML ®DOT ၍ଣᄴীሞʿʱؓ •® ® ®IIINSCLCCSCOCSCO®IIINSCLC CS5001 (LCB71ROR1 ADC) •ROR1ADCFIH•FIH7CS5001CS5001ROR1 ADC•9DLTMTDROR1CS500145CS5001ADC5BCS50012Ib/IIASCOESMOASH•CS5001MMAEROR1ADCCS5001BICCS5001ROR1/13ADCCS5001•ROR1ROR1IHC CS1001PD-L1 •P D - L 1I VN S C L CI I INSCLCR/R ENKTL ESCCGC/GEJPD-L1GIgG4 •IVNSCLC IVNSCLCMAANSCLCMAAEMAMHRAEMAGCPMHRA80RFIEMA180LoOIEMACROGCP IVNSCLCGEMSTONE-302OSNature Cancer •GC/GEJC GC/GEJC(CPS≥5)NDA GC/GEJC(CPS≥5)NDA GEMSTONE-303PFSOSLBAESMOPFSOS ၍ଣᄴীሞʿʱؓ •ESCC ESCCNDAESCCNDAESCCGEMSTONE-304PFSOSESMO GIGEMSTONE-304PFSOSNature Medicine •R/R ENKTL R/R ENKTLNDAR/RENKTLGEMSTONE-201R/RENKTLB 18A.05 NofazinlimabCS1003 PD-1 nofazinlimabLENVIMA®(lenvatinib)HCCIIIiDMCOS nofazinlimabFIH(CS1003-101)(British Journal of Cancer) CS3009RET •TFDARETNSCLCRETMTCRETTCNDA•RETNSCLCNDA•RETNSCLCI/IIARROWCancerRETNSCLC CS3007KIT/PDGFRA •BlueprintMedicinesFDA•Blueprint MedicinesEMAISMISM•ASCOGISTKITKITATPGIST•GIST1NAVIGATOR1/2(CS3007-101) CS3010IDH1 •R/R AML•R/R AML•R/R AML ၍ଣᄴীሞʿʱؓ ALK/ROS-1 •ROS1NSCLCROS1NSCLCROS1NSCLCpre-NDA/NDA ADC •ADCADCADCCS5006GPCR-xADC CS5005ADCCS5007ADCCS2011CS5007(CS2011)ADC •CS2009PD-1VEGFaCTLA-4INDPD-(L)1NSCLCHCC • • n o f a z i n l i m a b40GMP61nofazinlimabnofazinlimabCMC • • 544 ၍ଣᄴীሞʿʱؓ • IVNSCLCIIINSCLCIIINSCLCPFSPD-1/PD-L1R/R ENKTLESCC ROS1NSCLCROS1NSCLC •Blueprint Medicines BlueprintMedicinesBlueprintMedicines • CTLA-4(CS1002)2CS1002CS1002CS1002Ib/IIINDHCCNSCLCCS1002(SHR-8068)NSCLCIND •EQRx EQRxnofazinlimabnofazinlimabEMAMHRAMAAEQRxnofazinlimab • COVID-19 COVID-19 ၍ଣᄴীሞʿʱؓ